Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
K03861 (K0 3861; AUZ-454; K-03861; AUZ 454), an aminopyrimidine-phenyl urea analog, is novel and potent type II cyclin-dependent kinase-CDK2 inhibitor with potential anticancer activity. In that order, its Kd values are 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C). A canonical type II binding mode was revealed by the cocrystal structure of CDK2 in complex with K03861. K03861 works by interfering with cyclin binding.
Targets |
CDK2(C118L/A144C) (Kd = 9.7 nM); CDK2(A144C) (Kd = 15.4 nM); CDK2(C118L) (Kd = 18.6 nM); CDK2(WT) (Kd = 50 nM); CDK2(C118L/A144C-Cyclin B) (Kd = 134.1 nM)
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Enzyme Assay |
K03861 is an inhibitor of type II CDK2 with a Kd of 8.2 nM. AUZ 454 (K03861) competes with activating cyclin binding to inhibit CDK2 activity.
|
||
Cell Assay |
Cell Line: Caki-1 and ACHN cells
Concentration: 10 μM; 20 μM Incubation Time: 1, 2, 3, and 4 days Result: Inhibited cell proliferation in a CDK2-dependent manner. |
||
Animal Protocol |
|
||
References |
Molecular Formula |
C24H26F3N7O2
|
|
---|---|---|
Molecular Weight |
501.50
|
|
Exact Mass |
501.21
|
|
Elemental Analysis |
C, 57.48; H, 5.23; F, 11.36; N, 19.55; O, 6.38
|
|
CAS # |
853299-07-7
|
|
Appearance |
Solid powder
|
|
SMILES |
CN1CCN(CC1)CC2=C(C=C(C=C2)NC(=O)NC3=CC=C(C=C3)OC4=NC(=NC=C4)N)C(F)(F)F
|
|
InChi Key |
PWDLXPJQFNVTNL-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C24H26F3N7O2/c1-33-10-12-34(13-11-33)15-16-2-3-18(14-20(16)24(25,26)27)31-23(35)30-17-4-6-19(7-5-17)36-21-8-9-29-22(28)32-21/h2-9,14H,10-13,15H2,1H3,(H2,28,29,32)(H2,30,31,35)
|
|
Chemical Name |
1-[4-(2-aminopyrimidin-4-yl)oxyphenyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]urea
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.03.00
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9940 mL | 9.9701 mL | 19.9402 mL | |
5 mM | 0.3988 mL | 1.9940 mL | 3.9880 mL | |
10 mM | 0.1994 mL | 0.9970 mL | 1.9940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.